Literature DB >> 18201687

Characterization of clozapine-induced changes in synaptic plasticity in the hippocampal-mPFC pathway of anesthetized rats.

Machiko Matsumoto1, Hiroki Shikanai, Hiroko Togashi, Takeshi Izumi, Takeya Kitta, Riki Hirata, Taku Yamaguchi, Mitsuhiro Yoshioka.   

Abstract

Synaptic plasticity expressed as long-term potentiation (LTP) in the hippocampal-medial prefrontal cortex (mPFC) pathway is considered to be involved in cognitive function and learning and memory processes, but its synaptic mechanism remains unknown. The present study characterized LTP in the mPFC using the atypical antipsychotic clozapine, with a focus on dopaminergic modulation. The magnitude of LTP was facilitated by pretreatment with clozapine (20 mg/kg, i.p.), but not by the typical antipsychotic haloperidol (1 mg/kg, i.p.). Clozapine-induced LTP augmentation was blocked by the dopamine D(1) receptor antagonist SCH-23390 (10 microg/rat, i.c.v.), but not by the D(2) receptor antagonist remoxipride (10 microg/rat, i.c.v.) or the 5-HT(1A) receptor antagonist WAY-100635 (20 microg/rat, i.c.v.). SCH-23390 (10 microg/rat, i.c.v.) by itself did not affect LTP induction. The D(1) receptor agonist SKF-38393 (10 microg/kg, i.c.v.) facilitated LTP, mimicking the clozapine-induced response. Furthermore, in vivo microdialysis showed that transient increases in mPFC dopamine levels induced by tetanic stimulation sustained facilitation following clozapine administration (20 mg/kg, i.p.). These results demonstrate the importance of the D(1) receptor as a mediator of clozapine-induced LTP augmentation through enhanced dopaminergic activity. Augmentation of synaptic plasticity in the hippocampal-mPFC pathway via D(1) receptors appears to be responsible for the therapeutic effects of clozapine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18201687     DOI: 10.1016/j.brainres.2007.12.010

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  The serotonergic projection from the median raphe nucleus to the ventral hippocampus is involved in the retrieval of fear memory through the corticotropin-releasing factor type 2 receptor.

Authors:  Yu Ohmura; Takeshi Izumi; Taku Yamaguchi; Iku Tsutsui-Kimura; Takayuki Yoshida; Mitsuhiro Yoshioka
Journal:  Neuropsychopharmacology       Date:  2010-01-13       Impact factor: 7.853

2.  Subanalgesic ketamine enhances morphine-induced antinociceptive activity without cortical dysfunction in rats.

Authors:  Hiroki Shikanai; Sachiko Hiraide; Hidekazu Kamiyama; Tsukasa Kiya; Koji Oda; Yoshikazu Goto; Yoshiki Yanagawa; Kei-ichi Shimamura; Yukiko Goda; Hiroko Togashi
Journal:  J Anesth       Date:  2013-10-11       Impact factor: 2.078

Review 3.  Effect of second-generation antipsychotics on cognition: current issues and future challenges.

Authors:  S Kristian Hill; Jeffrey R Bishop; Donna Palumbo; John A Sweeney
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

Review 4.  Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies.

Authors:  Rae Price; Bahar Salavati; Ariel Graff-Guerrero; Daniel M Blumberger; Benoit H Mulsant; Zafiris J Daskalakis; Tarek K Rajji
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-05-10       Impact factor: 5.067

5.  A new strategy for antidepressant prescription.

Authors:  Francis Lavergne; Thérèse M Jay
Journal:  Front Neurosci       Date:  2010-11-19       Impact factor: 4.677

6.  Learning and generalization in schizophrenia: effects of disease and antipsychotic drug treatment.

Authors:  Daphna Shohamy; Perry Mihalakos; Ronald Chin; Binu Thomas; Anthony D Wagner; Carol Tamminga
Journal:  Biol Psychiatry       Date:  2009-12-24       Impact factor: 13.382

7.  The dreaming brain/mind: a role in understanding complex mental disorders?

Authors:  Armando D'Agostino; Ivan Limosani; Silvio Scarone
Journal:  Front Psychiatry       Date:  2012-01-31       Impact factor: 4.157

8.  Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation.

Authors:  Marion Rame; Dorian Caudal; Esther Schenker; Per Svenningsson; Michael Spedding; Thérèse M Jay; Bill P Godsil
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

Review 9.  Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems.

Authors:  Pietro De Rossi; Chiara Chiapponi; Gianfranco Spalletta
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.